Phase
Startup
Apoglyx
Apoglyx AB is focused on innovative and novel medicines for acute systemic inflammatory diseases like acute pancreatitis, COVID-19 and sepsis, where an overreaction of the immune system harms the body’s own organs.
The company is based on the fundamental discovery of aquaporins by Nobel Laureate professor Peter Agre, Johns Hopkins University Medical School, and the extensive, collaborative scientific work with ApoGlyx founders Søren Nielsen, and Michael Rützler, at Århus University, Denmark and Per Kjellbom, Lund University, to establish that aquaporins are key pharmaceutical targets in life-threatening diseases.
News
Non-invasive cardiac pressure monitoring device
Accelerated drug development in oncology
Medicines for acute systemic inflammatory diseases
Simplify medicine information through digital services
Cancer immunotherapies based in cell reprogramming
Cell factories for dairy processing
Antibiotic-free treatment for vaginal bacterial infections
Individualised information of the intestinal flora
Digital service for patients
Digital tool for meeting an allergy doctor
Digital communication tool for titrating medicine
Mobile systems for movement analysis
Innovative solutions for better health care
Medical device that reduces pain during vein operation
Prebiotics for irritable bowel syndrome
Digital assistive device for post-surgical rehabilitation
Nanotechnology based infection control
Bio-based vegan coating for fruits and vegetables
Therapeutics after stroke
Equipment that improves the function of cultivated cells
Male-Factor Infertility Diagnostics
Medtech solution for preventing pressure ulcers
Gene editing analysis solution
Stroke detection device
